HUTCHMED (China)

HUTCHMED (China) Limited ADR is an American depositary receipt representing shares of HUTCHMED (China) Limited, a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company’s current portfolio spans oncology and immunology research, clinical development, regulatory activities, manufacturing, and commercialization, with products and candidates aimed at addressing unmet medical needs across multiple therapeutic areas. HUTCHMED also operates other commercial businesses, including the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. Based in Hong Kong, the company serves markets in China and internationally through a combination of in-house development and commercial infrastructure. As an ADR, HUTCHMED (China) Limited provides investors with access to the company’s underlying ordinary shares in a U.S.-traded format.